Extracellular Matrix–Derived Damage-Associated Molecular Patterns (DAMP): Implications in Systemic Sclerosis and Fibrosis

Bale, Swarna; Verma, Priyanka; Varga, John; Bhattacharyya, Swati

doi:10.1016/j.jid.2023.04.030

Cited by 12 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 47 Internal activation signals include damage-associated molecular patterns (DAMPs) that are intracellular molecules released under significant tissue injury or cellular stress and bind as endogenous ligands on TLRs. 48 DAMPs-TLR interaction on fibroblasts directly activates these collagen-producing cells to generate large amounts of collagen contributing to ECM expansion typical of SSc and the complications of SSc. 47 Further, ligand activation of TLR on dendritic cells results in increased production of Th17-related cytokines including IL-1β, IL-17F, IL-21 IL-22, and IL-33 resulting in aberrant T cell polarization and profibrotic inflammation.…”

Section: Autoantibodies As Biomarkers In Sscmentioning

confidence: 99%

Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis

Muruganandam,

Ariza-Hutchinson,

Patel

et al. 2023

JIR

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, vasoinstability, and decreased perfusion with ischemia, inflammation, and exuberant fibrosis of the skin and internal organs. Biomarkers are analytic indicators of the biological and disease processes within an individual that can be accurately and reproducibly measured. The field of biomarkers in SSc is complex as recent studies have implicated at least 240 pathways and dysregulated proteins in SSc pathogenesis. Anti-nuclear antibodies (ANA) are classical biomarkers with well-described clinical classifications and are present in more than 90% of SSc patients and include anti-centromere, anti-Th/To, anti-RNA polymerase III, and anti-topoisomerase I antibodies. Transforming growth factor-β (TGF-β) is central to the fibrotic process of SSc and is intimately intertwined with other biomarkers. Tyrosine kinases, interferon-1 signaling, IL-6 signaling, endogenous thrombin, peroxisome proliferator-activated receptors (PPARs), lysophosphatidic acid receptors, and amino acid metabolites are new biomarkers with the potential for developing new therapeutic agents. Other biomarkers implicated in SSc-ILD include signal transducer and activator of transcription 4 (STAT4), CD226 (DNAX accessory molecule 1), interferon regulatory factor 5 (IRF5), interleukin-1 receptor–associated kinase-1 (IRAK1), connective tissue growth factor (CTGF), pyrin domain containing 1 (NLRP1), T-cell surface glycoprotein zeta chain (CD3ζ) or CD247, the NLR family, SP-D (surfactant protein), KL-6, leucine-rich α2-glycoprotein-1 (LRG1), CCL19, genetic factors including DRB1 alleles, the interleukins (IL-1, IL-4, IL-6, IL-8, IL-10 IL-13, IL-16, IL-17, IL-18, IL-22, IL-32, and IL-35), the chemokines CCL (2,3,5,13,20,21,23), CXC (8,9,10,11,16), CX3CL1 (fractalkine), and GDF15. Adiponectin (an indicator of PPAR activation) and maresin 1 are reduced in SSc patients. A new trend has been the use of biomarker panels with combined complex multifactor analysis, machine learning, and artificial intelligence to determine disease activity and response to therapy. The present review is an update of the various biomarker molecules, pathways, and receptors involved in the pathology of SSc.

show abstract

Section: Autoantibodies As Biomarkers In Sscmentioning

confidence: 99%